| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-09-23 |
| タイトル |
|
|
タイトル |
Cause of Mortality and Sarcopenia in Patients with Idiopathic Pulmonary Fibrosis Receiving Anti-Fibrotic Therapy |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
Antifibrotic therapy |
| キーワード |
|
|
主題 |
Idiopathic pulmonary fibrosis |
| キーワード |
|
|
主題 |
Skeletal muscle loss |
| キーワード |
|
|
主題 |
Sarcopenia |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| その他のタイトル |
|
|
その他のタイトル |
Sarcopenia in IPF receiving antifibrotics |
| 著者 |
Suzuki, Yuzo
Aono, Yuya
Kono, Masato
Hasegawa, Hirotsugu
Yokomura, Koushi
Naoi, Hyogo
Hozumi, Hironao
Karayama, Masato
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Nakamura, Hidenori
Suda, Takafumi
|
| 書誌情報 |
Respirology
巻 26,
号 2,
p. 171-179,
発行日 2021-02
|
| 出版者 |
|
|
出版者 |
John Wiley and Sons |
| 権利 |
|
|
権利情報 |
"This is the peer reviewed version of the following article: ""Cause of Mortality and Sarcopenia in Patients with Idiopathic Pulmonary Fibrosis Receiving Anti-Fibrotic Therapy"", Respirology; 26(2): p171-179, 2021, which has been published in final form at https://doi.org/10.1111/resp.13943. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited." |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Summary at Glance
Skeletal muscle wasting (sarcopenia) without obvious weight loss is commonly found in patients with IPF receiving antifibrotic therapy. Most study patients died of chronic respiratory failure and skeletal muscle loss was associated with worse outcomes in antifibrotic therapy, suggesting that sarcopenia prevention is crucial for patients with IPF. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
ABSTRACT
Background and objective: Recent research has highlighted the fundamental role of sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor outcomes. Anti-Fibrotic Therapy (AFT) preserves lung function by preventing the annual decline in forced vital capacity (FVC) and is associated with improved outcomes in patients with idiopathic pulmonary fibrosis (IPF). However, altered cause of death and prognostic implications of sarcopenia in patients with IPF receiving AFT remain unknown.
Methods: This study comprised two cohorts of patients with IPF receiving AFT, historical cohort of IPF patients without AFT and controls. The cause of mortality was compared with a historical cohort. Sarcopenia was assessed by measuring the cross-sectional area (ESMCSA) and muscle-attenuation (ESMMA) of erector spinae muscles via computed-tomography.
Results: Patients with IPF had smaller ESMCSA and lower ESMMA but similar body mass index (BMI) than controls, suggesting patients with IPF had skeletal muscle loss without any obvious body weight loss. The most common cause of mortality in patients receiving AFT was chronic respiratory failure, accounting for approximately 60%, and decreased proportions of lung cancer were found. Subsequently, low ESMCSA was an independent prognostic factor associated with worse survival rates. Furthermore, combined assessment of ESMCSA, %FVC-predicted, and BMI values provided clear prognostic distinction.
Conclusion: Patients with IPF receiving AFT showed skeletal muscle loss without obvious weight loss. These patients mostly died by chronic respiratory failure, and skeletal muscle wasting has prognostic significance, suggesting that preventing sarcopenia as well as preserving lung function is important for managing these patients. |
| 注記 |
|
|
内容記述 |
雑誌掲載タイトル：Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1323-7799 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1440-1843 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32969124 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1111/resp.13943 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
Respirology-26-171.pdf (1.4 MB)
